Abstract:
Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.
Abstract:
Disclosed herein are methods and compositions for lipid nanoparticles encapsulating a nucleic acid encoding for a CRISPR nucleic acid complementary to a HIV-1 gene. Also disclosed are lipid nanoparticle compositions, nucleotides, cells, and methods associated with the compositions.
Abstract:
Tunable nanoparticles and methods of use thereof are provided. In accordance with the instant invention, tunable nanoparticles comprising a metal nanoparticle core (e.g., a paramagnetic particle (e.g., USPIO) or a quantum dot) and a polymer linked to a metal binding moiety are provided. The polymer of the nanoparticle is bound to the metal nanoparticle core by the metal binding moiety and coats the metal nanoparticle core. In a particular embodiment, the metal binding moiety comprises bisphosphonate, pyrophosphate, or a derivative thereof. In a particular embodiment, the polymer is a hydrophilic polymer, an amphiphilic block copolymer or an ionic block copolymer.
Abstract:
Methods and compositions for treating central nervous system diseases and disorders are disclosed. In a particular embodiment, compositions comprising a nitrated alpha synuclein peptide are provided. The composition may further comprise an adjuvant that stimulates regulatory T cells and/or at least one pharmaceutically acceptable carrier.